One of the best things that can happen to clinical trials is to make the process smoother. That is exactly what the FDA is trying to do. They have outlined how developers of drugs targeting rare pediatric diseases to streamline their clinical development programs and encourage collaborating. This will reduce the total number of patients who would receive a placebo instead of a potentially helpful drug. To read more about the new guidance, click here.
FDA opens door to multiarm, multicompany clinical trials
